Evidence that the IL-6/IL-6 soluble receptor cytokine system plays a role in the increased skeletal sensitivity to PTH in estrogen-deficient women

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 6, 2002, Pages 2892-2898

  Masiukiewicz, Urszula S ^a   Mitnick, Maryann ^a   Gulanski, Barbara I ^a   Insogna, Karl L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 6; PARATHYROID HORMONE[1-34];

ADULT; ARTICLE; BONE METABOLISM; BONE REMODELING; CALCIUM BLOOD LEVEL; CALCIUM HOMEOSTASIS; CELL MATURATION; CLINICAL ARTICLE; CYTOKINE RELEASE; ESTROGEN DEFICIENCY; FEMALE; GENE TARGETING; HORMONAL REGULATION; HUMAN; MENOPAUSE; OSTEOCLAST; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; STROMA CELL;

ANIMALIA;

EID: 0036078458     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.87.6.8577     Document Type: Article

References (37)

1. Osteoclast differentiation factor is a ligand for osteoprotegrin/osteoclast-inhibitory factor and is identical to TRANCE/RANKL
2. The cell-surface form of colony-stimulating factor-1 is regulated by osteotropic agents and supports formation of multinucleated osteoclast-like cells
3. Interleukin-6 is produced by bone and modulated by parathyroid hormone
4. IL-6 is produced by osteoblasts and induces bone resorption
5. Regulation of cytokine expression in osteoblasts by parathyroid hormone: Rapid stimulation of interleukin-6 and leukemia inhibitory factor mRNA
6. Stimulation by parathyroid hormone of interleukin-6 and leukemia inhibitory factor expression in osteoblasts in an immediate-early gene response induced by cAMP signal transduction
7. Stimulation of interleukin-6 production by either calcitonin gene-related peptide or parathyroid hormone in two phenotypically distinct bone marrow-derived murine stromal cell lines
8. Parathyroid hormone induces interleukin-6 heterogenous nuclear and messenger RNA expression in murine calvarial organ cultures
9. Parathyroid hormone (1-34)-mediated interleukin-6 induction
10. Cytokine and hormonal stimulation of human osteosarcoma interleukin-11 production
11. Adenyl cyclase and IL-6 are downstream effectors of parathyroid hormone resulting in stimulation of bone resorption
12. A role for interleukin-6 in parathyroid hormone induced bone resorption in vivo
13. Interleukin-6 knock-out mice have secondary hyperparathyroidism and increased bone density
14. Selective femoral neck osteopenia is a marker for secondary hyperparathyroidism
15. Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism, and correlate with markers of bone resorption
16. Increased osteoclast development after estrogen loss: Mediation by interleukin-6
17. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion
18. Estrogen modulates parathyroid hormone-induced interleukin-6 production in vivo and in vitro
19. Estrogen protection against bone resorbing effects of parathyroid hormone infusion: Assessment by use of biochemical markers
20. Radioimmunoassay for middle region of human parathyroid hormone using an homologus antiserum with a carboxy-terminal fragment of bovine parathyroid hormone as radioligand
21. Nephrogenous cyclic AMP as a parathyroid function test
22. A microassay for 1,25-dihydroxyvitamin D not requiring high performance liquid chromatography
23. IL-6 negatively regulates IL-11 production in vitro and in vivo
24. 17β estradiol inhibits expression of human interleukin-6 promoter-reporter constructs by a receptor-dependent mechanism
25. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-κB and C/EBPβ
26. Repression of interleukin-6 gene expression by 17β-estradiol: Inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NF-kB by the estrogen receptor
27. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin-6
28. Elevated plasma levels of interleukin-6 in postmenopausal women do not correlate with bone density
29. Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: A population-based study
30. Circulating levels of cytokines that modulate bone resorption: Effect of age and menopause in women
31. Circulating cytokine levels in osteoporotic and normal women
32. Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause
33. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: A randomized controlled trial
34. Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: Four-year follow-up and comparison with healthy postmenopausal women
35. Effect of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: A population-based study
36. Parathyroid hormone induces hepatic production of bioactive interleukin-6 and its soluble receptor
37. Estrogen withdrawal augments PTH-induced IL-6 and IL-6 soluble receptor production by the liver